Interferon Alpha Plus 13-Cis-Retinoic Acid Modulation of BCL-2 Plus Paclitaxel for Recurrent Small Cell Lung Cancer (SCLC): An Eastern Cooperative Oncology Group Study (E6501)

BACKGROUND: Patients with recurrent small cell lung cancer (SCLC) have dismal outcomes. The failure of salvage therapy is due to the possible development of resistance mechanisms, such as the upregulation of the anti-apoptosis protein, Bcl-2. We conducted a phase II study to evaluate if modulation o...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Chemother Pharmacol
Hoofdauteurs: Pillai, Rathi N., Aisner, Joseph, Dahlberg, Suzanne E., Rogers, John S., DiPaola, Robert S., Aisner, Seena, Ramalingam, Suresh S., Schiller, Joan H.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2014
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4296897/
https://ncbi.nlm.nih.gov/pubmed/24858462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2427-7
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items